BRPI0707543B8 - composição de polipeptídeo e uso da mesma - Google Patents

composição de polipeptídeo e uso da mesma

Info

Publication number
BRPI0707543B8
BRPI0707543B8 BRPI0707543A BRPI0707543A BRPI0707543B8 BR PI0707543 B8 BRPI0707543 B8 BR PI0707543B8 BR PI0707543 A BRPI0707543 A BR PI0707543A BR PI0707543 A BRPI0707543 A BR PI0707543A BR PI0707543 B8 BRPI0707543 B8 BR PI0707543B8
Authority
BR
Brazil
Prior art keywords
polypeptide
seq
composition
vaccine
drug composition
Prior art date
Application number
BRPI0707543A
Other languages
English (en)
Inventor
Alan Stoloff Gregory
Romero Caparros-Wanderley Wilson
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38109631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0707543(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0602416A external-priority patent/GB0602416D0/en
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of BRPI0707543A2 publication Critical patent/BRPI0707543A2/pt
Publication of BRPI0707543B1 publication Critical patent/BRPI0707543B1/pt
Publication of BRPI0707543B8 publication Critical patent/BRPI0707543B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

polipeptídeo, composição de polipeptídeo, metodos para produzir um polipeptídeo e uma construção de polipeptídeos, composição de vacina ou medicamento contra influenza, metodo para produzir uma composição de vacina ou medicamento, uso de um polipeptídeo, uma composição de polipeptídeo, uma construção de polipeptídeo ou uma composição de vacina ou medicamento, e, método de tratamento ou prevenção de influenza provê-se um polipeptídeo não tendo mais do que 100 aminoácidos, cujo polipeptídeo compreende uma ou mais seqüências tendo pelo menos 60% de homologia com qualquer uma de seq id 1-6 ou compreende dois ou mais epítopos tendo 7 aminoácidos ou mais, cada epítopo tendo, pelo menos, 60% homologia com uma sub-seqüência de qualquer seq id 1-6, que tem o mesmo comprimento que o epítopo: seq id 1 dlealmewlktrpilspltkgilgfvftltvp, seq id 2, llyclmvmylnpgnysmqvklgtlcalcekqashs, seq id 3, dliflarsalilrgsvahksc, seq id 4 pgiadiedltllarsmvwrp, seq id 5 llidgtaslspgmmmgmfnmlstvlgvsilnlgq, seq id 6 iigilhlilwildrlffkcfyrlf em que o polipeptídeo é imunogênico em um vertebrado expressando um alelo do complexo de histocompatibilidade principal (mhc), e em que o polipeptídeo não é uma proteína do vírus de influenza completa.
BRPI0707543A 2006-02-07 2007-02-05 composição de polipeptídeo e uso da mesma BRPI0707543B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0602416A GB0602416D0 (en) 2006-02-07 2006-02-07 Peptide sequences and compositions
GB0602416.0 2006-02-07
GBGB0613977.8A GB0613977D0 (en) 2006-02-07 2006-07-13 Peptide sequences and compositions
GB0613977.8 2006-07-13
PCT/GB2007/000383 WO2007091030A2 (en) 2006-02-07 2007-02-05 Peptide sequences and compositions

Publications (3)

Publication Number Publication Date
BRPI0707543A2 BRPI0707543A2 (pt) 2011-05-03
BRPI0707543B1 BRPI0707543B1 (pt) 2020-11-24
BRPI0707543B8 true BRPI0707543B8 (pt) 2021-05-25

Family

ID=38109631

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707543A BRPI0707543B8 (pt) 2006-02-07 2007-02-05 composição de polipeptídeo e uso da mesma

Country Status (23)

Country Link
US (10) US8475802B2 (pt)
EP (6) EP2383284B1 (pt)
JP (1) JP5603551B2 (pt)
KR (1) KR20080100441A (pt)
CN (3) CN101395176B (pt)
AP (1) AP2646A (pt)
AT (1) ATE534660T1 (pt)
AU (1) AU2007213562A1 (pt)
BR (1) BRPI0707543B8 (pt)
CA (1) CA2641602A1 (pt)
DK (4) DK2383285T3 (pt)
EA (1) EA017387B1 (pt)
ES (4) ES2790730T3 (pt)
GB (1) GB0613977D0 (pt)
HK (1) HK1249115A1 (pt)
IL (2) IL193232A (pt)
MX (1) MX2008010113A (pt)
NO (1) NO20083416L (pt)
NZ (1) NZ570553A (pt)
PL (4) PL3263589T3 (pt)
PT (1) PT1991563E (pt)
SG (1) SG169392A1 (pt)
WO (1) WO2007091030A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0613977D0 (en) * 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
MX2010001284A (es) 2007-08-02 2010-08-31 Biondvax Pharmaceuticals Ltd Vacunas contra la influenza con multiepitope multimerico.
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2976814C (en) 2007-08-27 2022-12-13 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods for treating influenza
EP2195466B1 (en) 2007-10-01 2012-10-10 Longhorn Vaccines & Diagnostics, LLC Method of storing biological specimens
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
GB0719526D0 (en) 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
EP2072529A1 (en) * 2007-12-21 2009-06-24 basisnote AG MHC rapid assay used for the customization of odours
FR2962739B1 (fr) * 2010-07-13 2014-01-31 Univ Claude Bernard Lyon Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2013093514A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccines - peptides
EP2806890A4 (en) 2012-01-26 2015-09-02 Longhorn Vaccines & Diagnostics Llc COMPOSITIONAL ANTIGEN SEQUENCES AND VACCINES
EP3231441A4 (en) * 2014-12-10 2018-10-31 Vaxsia Biomedical Inc. Novel protein structure produced by effective antibody used for immunization
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
CN106310214A (zh) * 2015-06-30 2017-01-11 中国科学院上海巴斯德研究所 流感病毒蛋白与宿主蛋白cpsf30的相互作用在抑制癌细胞增殖中的应用
JP2019064924A (ja) * 2016-02-24 2019-04-25 Ａｇｃ株式会社 インフルエンザワクチン
KR101888751B1 (ko) * 2016-09-22 2018-09-21 이화여자대학교 산학협력단 인플루엔자 b 백신
BR112019013402A2 (pt) 2016-12-28 2020-03-03 Invvax, Inc. Vacinas de influenza
EP3730620A4 (en) * 2017-12-21 2022-01-05 Green Biomed, Inc. CROSS-IMMUNIZING ANTIGEN VACCINE AND METHOD OF ITS MANUFACTURING
KR20230041775A (ko) * 2020-07-21 2023-03-24 플루젠, 인코퍼레이티드 인플루엔자 바이러스 백본

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981782A (en) 1987-05-14 1991-01-01 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
US5741493A (en) * 1991-01-24 1998-04-21 Pasteur Merieux Serums Et Vaccins Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive
IL101639A0 (en) * 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
EP1704868A1 (en) * 1992-08-07 2006-09-27 Pharmexa Inc. HLA binding peptides and their uses
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
IL109664A0 (en) 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
AU3727895A (en) 1994-09-30 1996-04-26 St. Jude Children's Research Hospital Nucleic acid encoding mutant matrix proteins useful for attenuation or enhancement of influenza a virus
US7269219B1 (en) * 1997-02-14 2007-09-11 At&T Corp. Non-linear quantizer for video coding
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
JP2001151698A (ja) * 1999-09-10 2001-06-05 Nichiko Pharmaceutical Co Ltd インフルエンザワクチン
WO2002026252A1 (en) 2000-08-10 2002-04-04 Tsinghua University A vaccine for influenza virus and its preparation
KR20030061810A (ko) * 2000-09-25 2003-07-22 폴리문 사이언티픽 임무노이비오로기쉐 포르슝 게엠베하 생균 백신과 제조 방법
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US20050013826A1 (en) * 2002-12-20 2005-01-20 Shneider Alexander M. Vaccine compositions and methods
CA2807534A1 (en) * 2003-02-25 2005-02-17 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
RU2005131016A (ru) * 2003-03-07 2006-06-10 Мерк энд Ко., Инк. (US) Вакцина вируса гриппа
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
DE102004052026B4 (de) * 2003-11-07 2015-08-27 Totankako Co., Ltd. Kollektor
FR2863758B1 (fr) * 2003-12-11 2006-07-14 Centre Nat Rech Scient Cellule de commande electronique pour diode electroluminescente organique d'afficheur a matrice active, procedes de fonctionnement et afficheur
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
MX358750B (es) * 2005-04-21 2018-08-31 Univ Florida Materiales y metodos para el control de enfermedades respiratorias en caninos.
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
CA2638815A1 (en) 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions

Also Published As

Publication number Publication date
EP2383284A3 (en) 2012-05-30
CN102807608A (zh) 2012-12-05
IL251867A0 (en) 2017-06-29
EA017387B1 (ru) 2012-12-28
US20190365883A1 (en) 2019-12-05
DK2383284T3 (en) 2016-12-12
EP3263589A3 (en) 2018-02-14
CN102382179A (zh) 2012-03-21
JP5603551B2 (ja) 2014-10-08
CN102382179B (zh) 2014-01-22
WO2007091030A3 (en) 2007-11-08
US8475802B2 (en) 2013-07-02
US20120219575A1 (en) 2012-08-30
IL251867B (en) 2018-06-28
NZ570553A (en) 2012-08-31
US11439702B2 (en) 2022-09-13
US10335480B2 (en) 2019-07-02
HK1249115A1 (en) 2018-10-26
ES2374841T3 (es) 2012-02-22
EP3320918A2 (en) 2018-05-16
BRPI0707543A2 (pt) 2011-05-03
US10765734B2 (en) 2020-09-08
US20130243804A1 (en) 2013-09-19
DK3263589T5 (da) 2020-05-25
EP2383285B1 (en) 2017-07-12
EP3320918A3 (en) 2018-08-01
US20100047275A1 (en) 2010-02-25
EA200870237A1 (ru) 2009-06-30
CN102807608B (zh) 2015-01-21
BRPI0707543B1 (pt) 2020-11-24
US20230233660A1 (en) 2023-07-27
US8444995B2 (en) 2013-05-21
KR20080100441A (ko) 2008-11-18
EP2383284A2 (en) 2011-11-02
AU2007213562A2 (en) 2008-11-20
EP2383285A2 (en) 2011-11-02
PL2383285T3 (pl) 2017-11-30
NO20083416L (no) 2008-11-07
WO2007091030A2 (en) 2007-08-16
US9889191B2 (en) 2018-02-13
US9446116B2 (en) 2016-09-20
EP3263589A2 (en) 2018-01-03
DK1991563T3 (da) 2012-01-23
MX2008010113A (es) 2009-01-19
US20170028053A1 (en) 2017-02-02
EP3263589B1 (en) 2020-03-25
ES2790730T3 (es) 2020-10-29
CN101395176A (zh) 2009-03-25
DK3263589T3 (da) 2020-05-11
PL2383284T3 (pl) 2017-07-31
PL3263589T3 (pl) 2020-07-13
SG169392A1 (en) 2011-03-30
AP2008004571A0 (en) 2008-08-31
ES2611034T3 (es) 2017-05-04
US20200397889A1 (en) 2020-12-24
EP1991563B1 (en) 2011-11-23
JP2009526028A (ja) 2009-07-16
EP2383285A3 (en) 2012-05-16
US20180185470A1 (en) 2018-07-05
ES2635590T3 (es) 2017-10-04
IL193232A (en) 2017-05-29
US10279032B2 (en) 2019-05-07
GB0613977D0 (en) 2006-08-23
EP1991563A2 (en) 2008-11-19
EP3620463A1 (en) 2020-03-11
ATE534660T1 (de) 2011-12-15
AU2007213562A1 (en) 2007-08-16
CA2641602A1 (en) 2007-08-16
DK2383285T3 (en) 2017-08-28
US20180147277A1 (en) 2018-05-31
US20190201519A1 (en) 2019-07-04
PT1991563E (pt) 2011-12-29
PL1991563T3 (pl) 2012-02-29
CN101395176B (zh) 2013-02-06
AP2646A (en) 2013-04-17
EP2383284B1 (en) 2016-08-24
IL193232A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
BRPI0707543B8 (pt) composição de polipeptídeo e uso da mesma
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
BR112022014627A2 (pt) Vacina contra coronavírus
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
BRPI0412202A (pt) emplastro para imunização tendo um arranjo de microprojeções, e método
BR0311777A (pt) Composição de vesìcula meningocócica multivalente, vacina para o tratamento de doença neisserial, métodos para fabricação de composição de vesìcula meningocócica multivalente e para prevenção ou tratamento de doença neisserial, e, uso de uma quantidade imunologicamente eficaz da vacina
BR112012018951B8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112012024806A2 (pt) membro de fixação arcado e implante intervertebral
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
BRPI0208183B8 (pt) peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
BR112015013183A2 (pt) proteínas de fusão para uso como aperfeiçoadores imunogênicos para indução de respostas de células t específicas para antígenos
BR0014386A (pt) Composição
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
BRPI0711608B8 (pt) composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
CO6341637A2 (es) \\\\\\\"composiciones y metodos novedosos\\\\\\\"
PE20121685A1 (es) Antigeno ndv recombinante y usos del mismo
BRPI0808599A2 (pt) "ácido nucléico, vacina, composição farmacêutica, uso de um ácido nucléico e método para estimular uma imunoresposta versus um epítopo das células t"
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
BR0309570A (pt) Fatores camp quiméricos para vacinação contra infecção por streptococcus
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.4 NA RPI NO 2594 DE 24/09/2020 POR TER SIDO INDEVIDA.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/02/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.